Filing Flows › Health Care › Vaso (VASO)
Vaso (VASO) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Vaso (VASO) Q2 2026 earnings results →
Q2 2026 Revenue down 44% year over year to $11.2M · 5¢ of every $1 of revenue kept as net profit · operating margin 8.7%
Vaso made $11.2M in Q2 2026 (-44% Y/Y): Commissions $10.5M, Equipment Sales and Services $693K. Operating margin 8.7%, net earnings $544K. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $11.2M in Q2 2026, down 44% year over year and down 42% from the previous quarter. Professional Sales Services was the largest line at 94% of revenue. Medical Equipment Service lost $1K year over year (down 3%), 0% of the total change.
Gross margin was 79.5%, up 39.7 points from Q2 2025. Operating profit was $1.0M, a 8.7% margin (up 8.2 points year over year). Operating expenses grew 1% against a revenue fall of 44%. The fastest-growing cost line was Research & development (+27%). Net earnings were $544K. The effective tax rate was 41.6%.
Operating cash flow was $17.4M (up 157% year over year), 3207% of net earnings. Non-cash charges added back $229K of depreciation and amortization and $11K of share-based compensation. Working capital and other items added $16.7M. Capital expenditures of $504K left free cash flow of $16.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $11.2M | -44% | 8.7% | $544K | $17.4M |
| Q1 2026 | 10-Q | May 15, 2026 | $19.4M | -0.5% | -6.9% | −$887K | −$12.6M |
| Q4 2025 | 10-K | Mar 31, 2026 | $27.0M | -0.1% | -10.3% | $1.1M | $261K |
| Q3 2025 | 10-Q | Nov 14, 2025 | $22.7M | +9% | 6.8% | $1.7M | $2.8M |
| Q2 2025 | 10-Q | Aug 14, 2025 | $20.0M | -1% | -2.1% | −$197K | $6.8M |
| Q1 2025 | 10-Q | May 15, 2025 | $19.5M | +4% | -6.3% | −$1.1M | −$566K |
| Q4 2024 | 10-K | Mar 31, 2025 | $27.0M | +23% | 8.0% | $2.1M | −$367K |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Vaso against its Electromedical & Electrotherapeutic Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -44% against the peers' median +14%. Operating margin: 8.7% against the peers' median 7.2%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| VASO Vaso | Q2 2026 | $11.2M | -44% | 8.7% |
| MDT Medtronic | Q1 FY27 | $9.8B | +14% | 18.1% |
| ITGR Integer Holdings | Q3 2026 | $450M | -4% | 6.3% |
| LIVN LivaNova | Q3 2026 | $393M | +10% | 7.2% |
| CNMD Conmed | Q3 2026 | $336M | -0.7% | 11.1% |
| TMDX TransMedics Group | Q3 2026 | $203M | +41% | 13.9% |
| AXGN Axogen | Q3 2026 | $75.8M | +26% | 1.3% |
| OM Outset Medical | Q3 2026 | $33.6M | +14% | -36.5% |
| CBLL Ceribell | Q3 2026 | $29.3M | +30% | -70.0% |
Source: Vaso 10-Q on SEC EDGAR · CIK 839087 · Electromedical & Electrotherapeutic Apparatus
More on VASO
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results